InvestorQ : I am a shareholder in APL Apollo Tubes and in Alkem? Can you tell me about the latest quarterly results announced by both the companies?
Rashi Mehra made post

I am a shareholder in APL Apollo Tubes and in Alkem? Can you tell me about the latest quarterly results announced by both the companies?

Answer
image
Archita Jajjoo answered.
2 months ago
Follow

Let me talk about APL Apollo Tubes first. The company witnessed 62.9% growth in sales revenues for Q4FY22 at Rs4,080 crore. FY22 full year revenues were up 53.7% at Rs12,625 crore. APL Apollo Tubes reported 27% growth in sales volumes at 552K tonnes for Q4FY22 while for full year the sales volumes was up 7% at 1,755K tonnes. EBITDA per tonne for Q4 FY22 was up 2% at Rs4,823. For FY22, ROE was 28.8% while ROCE stood at a healthy 34.5%.

Let me now turn to the profit performance of APL Apollo Tubes. Net profits for Q4FY22 were up 36.73% at Rs163 crore and could have been still better but for input cost pressures. EBITDA for Q4FY22 was up 29% at Rs270 crore as interest cost fell 30% yoy on debt reduction program. Net margins were 3.99% in Q4FY22 quarter compared to 4.79% in Q4FY21. However, the NPM was higher compared to 3.70% in Q3FY22.

I will not turn to the second company held by you, the pharma major Alkem Ltd. Sales growth for the quarter was 13.31% at Rs2,484 crore. FY22 full year revenues were up 19.95% at Rs10,634 crore. While Alkem India sales were up 16.7% at Rs1,719 crore, global sales were up 7.3% at Rs741 crore. There was significant pricing pressures in the US markets resulting in subdued revenue growth overall, even as volumes remained robust

However, profits of Alkem fell sharply by -55.2% at Rs108 crore for Q4FY22. This was on account of significant pricing pressures in the US markets, as already stated. India growth was led by anti-infectives, vitamins and pain management verticals. Net margins stood at 4.33% in Q4FY22 quarter compared to 10.95% and 20.07% in Q3FY22. Incidentally, the EBITDA margins improved by 30 bps to 13.6%. R&D costs were a healthy 6.6% of revenues.

5 Views